Michael Morris

Feb 15, 2024 | urotoday.com | Michael Morris

Daniel George hosts Michael Morris to discuss pivotal studies influencing the use of Pluvicto (lutetium PSMA-617) in treating prostate cancer. The conversation begins with the VISION study, which led to Pluvicto's approval by demonstrating significant improvements in radiographic progression-free survival (rPFS) and overall survival (OS) for patients with PSMA-positive disease. Dr. Morris outlines the liberal criteria for PSMA positivity used in the study, emphasizing its real-world applicability.

Feb 11, 2024 | nature.com | Himisha Beltran |Michael Morris |Daniel George |Andrew Armstrong

AbstractCALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in overall survival (OS), there were improved intermediate outcomes suggesting that subsets of men may derive benefit from this combination.

Feb 9, 2024 | urotoday.com | Michael Morris

Read the Full Video TranscriptMichael Morris: And Johannes, Jeremie, Chuck, Tom, wherever you are, thank you so much for this conference. It's really so nice. But also, thanks to everybody who's flown from far and wide to come together. This is such a nice, intimate, academic experience. We really appreciate it. All right, we're going to talk about PSMA PET appropriate use criteria, and I think we can save ourselves a little bit of time by not repeating what everyone has said about certain slides.

Feb 9, 2024 | urotoday.com | Michael Morris

Read the Full Video TranscriptMichael Morris: What a great whirlwind tour. Thanks, Matt. All right. So, I'm going to be talking about VISION and TheraP, and obviously, everybody here has been really involved in these two trials and couldn't have been done without everyone's hard work. I only have seven minutes per trial, so don't feel offended anybody if we cruise right through here. All right. First of all, VISION.

Nov 17, 2023 | urotoday.com | Michael Morris

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here with Professor Michael Morris of Memorial Sloan Kettering to talk about how we can improve access and design of clinical trials to ensure that more patients have the ability to participate. Thank you so much for being here with me today. Michael Morris: Thanks for having me. Alicia Morgans: Wonderful.